Joel C. Barrish
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)Jnana Therapeutics (United States)(US)Bristol-Myers Squibb (Sweden)(SE)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, HIV/AIDS drug development and treatment, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays(2004)1,285 cited
- → 2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of N -(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan -Src Kinase Inhibitor(2006)395 cited
- → A new facile method for the synthesis of 1-arylimidazole-5-carboxylates(2000)178 cited
- → A stereoselective synthesis of 1,3-diol derivatives and application to the ansa bridge of rifamycin S(1983)172 cited
- → Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers(2016)